Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-02-11 4:06 pm Purchase | 2021-12-31 | 13G | Neoleukin Therapeutics, Inc. NLTX | Ulge Umut | 156,387 7.300% | 9,115 (+6.19%) | Filing History |
| 2022-02-10 11:10 am Purchase | 2022-02-10 | 13G | Neoleukin Therapeutics, Inc. NLTX | PICTET ASSET MANAGEMENT SA | 128,714 6.070% | 128,714 (New Position) | Filing History |
| 2022-02-02 7:18 pm Sale | 2021-12-31 | 13G | Neoleukin Therapeutics, Inc. NLTX | BlackRock Inc. BLK | 130,232 6.100% | -4,013 (-2.99%) | Filing History |
| 2021-02-16 4:10 pm Purchase | 2020-12-31 | 13G | Neoleukin Therapeutics, Inc. NLTX | Redmile Group LLC | 209,783 9.900% | 209,783 (New Position) | Filing History |
| 2021-02-16 12:05 pm Sale | 2020-12-31 | 13G | Neoleukin Therapeutics, Inc. NLTX | EcoR1 Capital, LLC | 156,135 7.500% | -39,659 (-20.26%) | Filing History |
| 2021-02-12 4:27 pm Sale | 2020-12-31 | 13G | Neoleukin Therapeutics, Inc. NLTX | Ulge Umut | 147,272 6.980% | -8,323 (-5.35%) | Filing History |
| 2021-02-12 4:25 pm Sale | 2020-12-31 | 13G | Neoleukin Therapeutics, Inc. NLTX | Silva Manzano Daniel Adriano | 146,907 6.960% | -8,688 (-5.58%) | Filing History |
| 2021-02-02 3:13 pm Purchase | 2020-12-31 | 13G | Neoleukin Therapeutics, Inc. NLTX | BlackRock Inc. BLK | 134,246 6.400% | 134,246 (New Position) | Filing History |
| 2020-12-23 5:11 pm Purchase | 2020-07-07 | 13D | Neoleukin Therapeutics, Inc. NLTX | BAKER BROS. ADVISORS LP | 211,491 9.990% | 21,241 (+11.16%) | Filing History |